Name: Andrew A. Lane, MD, PhD discuss results from a phase 2 Study
Uploaded: 2025-12-18T00:00:00+00:00
Description: Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)

Related Presenters

Andrew Lane, MD, PhD

Medical Oncology

View full profile